<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82665">
  <stage>Registered</stage>
  <submitdate>12/03/2008</submitdate>
  <approvaldate>18/03/2008</approvaldate>
  <actrnumber>ACTRN12608000140358</actrnumber>
  <trial_identification>
    <studytitle>An Open-Label, Multi-Center, Randomized Study Evaluating the Safety and Efficacy of Flutcasone Propionate Nasal Drops, Nasal Spray and Suspension for Nebulization via Nasal Inhalation in Post-Surgical Subjects with Chronic Sinusitis</studytitle>
    <scientifictitle>A randomised controlled trial evaluating the safety and efficacy of Flutcasone Propionate Nasal Drops, Nasal Spray and Suspension for Nebulization in post-surgical participants with chronic sinusitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Naryx Pharma, Inc: NRYX-FLUT-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Sinusitis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>a) Flixonase Nasule Drops one nasule per day for both nostrils 400 mcg per day for 4 wks b) Beconase Allergy &amp; Hayfever 24 Hour nasal spray 2 spays per nostril twice per day 400 mcg/day for four weeks c) Flixotide Nebules 2 mg/mL nebule, via nasal inhalation once per day 400 mcg/day for four weeks</interventions>
    <comparator>There are no control treatments.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Comparison from the change of baseline (entry) in the average Subject-Rated Total Sinus Symptom Score during the fourth (last) week of therapy for each method of administration</outcome>
      <timepoint>Measured at Days -13 to 0, days 1, 15, 29 and 36.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of percentage of participants experiencing improvement at Day 29 (Treatment period) based on the Physician-Rated Global Improvement Score</outcome>
      <timepoint>Day 29</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Changes from baseline in weekly average sum scores for the subject rated sinus symptoms of nasal congestion, post-nasal drip, and one of the following symptoms (identified as the worst at Screening): facial or sinus pain, facial or sinus pressure, or sinus headache; during the fourth week of therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Females who are either pregnant, breastfeeding or of child bearing potential not using adequate birth control.
2. Evidence of infection by purulent drainage from an open sinus cavity visualized by nasal endoscopy 3. Nasal polyposis causing obstruction of any open sinus cavity rending them inaccessaible to endoscopic exam 4. Known allergy or hypersensitivity of fluticasone propionate or any of the formulation components of the product. 5. any disease or condition requiring corticosteroid therapy 6.Any use of antibiotics or anti-fungals, decongestants and/or antihistamines within the past 7 days prior to randomization 7. Any condition that would make the administration of fluticasone propionate clinically inadvisable 8. Use of any systemic corticosteroids within the past 30 days prior to screening 9. Use of nasal or inhaled corticosteroids within the past 14 days prior to randomization 10. Use of mast cell or leukotriene inhibitors when necessary within the past 14 days prior to randomization</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was concealed by central randomization via computer-generated schedule</concealment>
    <sequence>Participants will be randomized to one of three treatment groups in accordance with a computer-generated randomization schedule by a study statistician.  Once a subject is eligiable for randomization, he/she will be assigned the appropriate treatment arm.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>12/07/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3002</postcode>
    <postcode>5000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Naryx Pharma, Inc.</primarysponsorname>
    <primarysponsoraddress>Suite A
5464 Carpinteria Avenue
Carpinteria CA 93013</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Naryx Pharma, Inc.</fundingname>
      <fundingaddress>Suite A
5464 Carpinteria Avenue
Carpinteria CA 93013</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Trident Clinical Research</sponsorname>
      <sponsoraddress>Trident House
124 Lipson Street
Port Adelaide South Australia 5015</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multi-center, randomized, parallel-group, open-label, 2 treatment group study to evaluate the safety and efficacy of Fluticasone Proprionate Nasal Drops, Nasal Spray and Suspension for Nebulization via Nasal Inhalation for the treatment of chronic sinusitis in post-surgical subjects 18 years of age and older.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Victorian Eye and Ear Hospital (RVEEH) Human Research and Ethics Committee</ethicname>
      <ethicaddress>RVEEH Human Research and Ethics Committee
32 Gisborne Street
East Melbourne Victoria 3002</ethicaddress>
      <ethicapprovaldate>16/04/2007</ethicapprovaldate>
      <hrec>07/751H</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Research Ethics Committe</ethicname>
      <ethicaddress>RAH Research Ethics Committee
Level 3
Hanson Institute
North Terrace
Adelaide South Australia 5000</ethicaddress>
      <ethicapprovaldate>17/07/2007</ethicapprovaldate>
      <hrec>070622</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Minh Pham</name>
      <address>Trident Clinical Research
124 Lipson Street
Port Adelaide South Australia 5015</address>
      <phone>+61 8 84473500</phone>
      <fax>+61 8 84473511</fax>
      <email>mpham@tridentcr.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Elsi Mathews, Clinical Project Manager</name>
      <address>Naryx Pharma, Inc.
Suite 3203760
4225 Executive Square
La Jolla CA 9</address>
      <phone>8584584200 ext. 231</phone>
      <fax>8584584350</fax>
      <email>emathews@naryxpharma.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Cathleen Maguire, SCRA</name>
      <address>Trident Clinical Research
Trident House
124 Lipson Street
Port Adelaide South Australia 5015</address>
      <phone>+61449259250</phone>
      <fax>+61 8 93850107</fax>
      <email>cmaguire@tridentcr.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>